Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIASTAT vs STELAZINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.
Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.
Status epilepticus (FDA-approved for acute management),Breakthrough seizures in patients on stable antiepileptic regimen (FDA-approved),Preoperative anxiety (off-label),Alcohol withdrawal syndrome (off-label),Muscle spasm (off-label)
Schizophrenia,Short-term treatment of generalized non-psychotic anxiety (off-label)
Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
Adults: 2-10 mg orally twice daily; maximum 40 mg/day.
30–60 hours for diazepam; nordazepam (active metabolite) 50–120 hours. Prolonged in elderly, liver disease, and neonates
Terminal elimination half-life is approximately 24-30 hours (up to 40 hours in chronic use). Clinical context: Steady-state is reached in 5-7 days; allows once- or twice-daily dosing.
Primarily hepatic via CYP2C19 and CYP3A4; active metabolite desmethyldiazepam (with long half-life); minor pathways include glucuronidation.
Hepatic via CYP450 enzymes (primarily CYP2D6); also undergoes N-demethylation and sulfoxidation.
Renal (primarily as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal minimal
Primarily renal (metabolites and unchanged drug; ~50% as metabolites); biliary/fecal excretion accounts for <20%.
98–99%; primarily albumin
92-97% bound to albumin and alpha-1 acid glycoprotein.
0.8–1.0 L/kg; increased in obesity (1.5–2.5 L/kg), redistribution to adipose tissue prolongs half-life
Approximately 18-30 L/kg (0.5-1.5 L/kg). Clinical meaning: Extensive tissue distribution with high CNS penetration.
Rectal: 90% (relative to IV, complete absorption). Oral: 100%
Oral: ~40% (due to first-pass metabolism); IM: 100%.
No specific dose adjustment required for renal impairment; however, use with caution in severe impairment (Cr Cl <10 m L/min) due to prolonged half-life.
No specific dose adjustment recommended; use caution in severe renal impairment.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Reduce dose by 75% or avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use or reduce dose by 75%.
Children 2-5 years: 0.5 mg/kg (max 20 mg) rectally. Children 6-11 years: 0.3 mg/kg (max 20 mg) rectally. Children 12+ years: same as adult dosing. May repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
Children 6-12 years: 1 mg 1-2 times daily; increase gradually up to 15 mg/day. Children >12 years: adult dosing.
Initiate at lower end of dosing range (e.g., 0.1-0.15 mg/kg, max 10 mg) due to increased sensitivity and risk of falls; monitor for prolonged sedation and respiratory depression.
Initiate at 1-2 mg twice daily; titrate slowly due to increased sensitivity and risk of orthostatic hypotension and extrapyramidal symptoms.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.
Increased mortality in elderly patients with dementia-related psychosis.
Risk of respiratory depression, especially with concomitant CNS depressants; tolerance and physical dependence may develop; withdrawal symptoms including seizures after abrupt discontinuation; caution in elderly, debilitated patients, and those with hepatic impairment; may cause drowsiness or dizziness; not recommended for use in pregnancy (neonatal withdrawal).
Tardive dyskinesia, neuroleptic malignant syndrome, QT prolongation, leukopenia/neutropenia/agranulocytosis, seizure threshold lowering, anticholinergic effects, hypotension, cholestatic jaundice, ocular changes (corneal/lenticular deposits).
Known hypersensitivity to diazepam or any benzodiazepine; myasthenia gravis; severe respiratory insufficiency; severe hepatic insufficiency; sleep apnea syndrome; narrow-angle glaucoma (in patients receiving anticholinergic therapy).
Comatose states, CNS depression (e.g., barbiturates, alcohol), bone marrow depression, blood dyscrasias, hepatic disease, hypersensitivity to phenothiazines.
No specific food interactions. Avoid grapefruit juice as it may increase diazepam levels. Alcohol can potentiate CNS depression.
Avoid alcohol and CNS depressants. Grapefruit juice may increase drug levels; avoid concurrent use. Limit caffeine intake. No specific dietary restrictions, but monitor weight gain due to increased appetite.
DIASTAT (diazepam) is classified as Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip and palate, when used during the first trimester. Second and third trimesters: Chronic use may lead to fetal dependence and withdrawal symptoms postnatally; risk of floppy infant syndrome (hypotonia, lethargy, sucking difficulties) when administered near term.
First trimester: Limited data; possible increased risk of congenital malformations (neural tube defects, cardiovascular) based on some retrospective studies. Second/third trimesters: Risk of extrapyramidal symptoms, jaundice, and hyperreflexia in neonates with late exposure. Case reports of neonatal withdrawal and EPS. Not a known major teratogen but use only if benefits outweigh risks.
Diazepam is excreted into breast milk with an M/P ratio of approximately 0.2-0.5. The American Academy of Pediatrics recommends use with caution due to potential accumulation and sedation in the infant. Avoid chronic use; if necessary, monitor infant for sedation, poor feeding, and weight gain.
Excreted in breast milk in small amounts; relative infant dose est. ~0.1-0.5% of maternal weight-adjusted dose. M/P ratio not established. Monitor infant for sedation, EPS, and poor feeding. Generally considered compatible with breastfeeding with caution.
Due to increased volume of distribution and altered protein binding in pregnancy, total clearance of diazepam may be increased, potentially requiring higher doses to achieve therapeutic effect. However, routine dose adjustment is not recommended without clinical monitoring. Use lowest effective dose for shortest duration. Caution in third trimester due to increased risk of neonatal effects.
Increased clearance in pregnancy may necessitate dose titration. Start at low end of dosing range; increase gradually based on response and tolerability. Monitor for relapse. Postpartum dose may need reduction due to restored clearance. No specific PK studies available; clinical judgment advised.
DIASTAT (diazepam rectal gel) is a formulation for acute management of seizure clusters. Administer rectally; monitor for respiratory depression, especially with concomitant CNS depressants. Do not exceed 5 doses per month or use for more than 5 episodes per month due to tolerance risk. Have flumazenil available for reversal.
Extrapyramidal symptoms (EPS) are common; use benztropine prophylactically in young males. Monitor for QT prolongation, especially in elderly. Avoid in patients with history of tardive dyskinesia. Can cause orthostatic hypotension; titrate slowly. Neuroleptic malignant syndrome (NMS) rare but serious; discontinue immediately if hyperthermia, rigidity, autonomic instability occur.
Use only as directed for episodes of increased seizure activity.,Administer rectally; do not reuse diapers/suppositories.,Monitor for drowsiness, dizziness, or breathing problems.,Avoid alcohol and other CNS depressants.,Store at room temperature; protect from light.,Seek emergency care if seizures last longer than usual or breathing is difficult.
Take exactly as prescribed; do not stop abruptly.,May cause dizziness upon standing; rise slowly from sitting or lying down.,Report any involuntary muscle movements, stiffness, or tremors to your doctor.,Avoid alcohol and other central nervous system depressants.,May cause drowsiness; use caution when driving or operating machinery.,Notify your doctor if you experience rapid heartbeat, fainting, or fever with muscle rigidity.,Avoid exposure to extreme heat (can impair body temperature regulation).,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIASTAT vs STELAZINE, answered by our medical review team.
DIASTAT is a Benzodiazepine Anticonvulsant that works by Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.. STELAZINE is a Phenothiazine Antipsychotic that works by Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIASTAT and STELAZINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIASTAT is: Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.. The standard adult dose of STELAZINE is: Adults: 2-10 mg orally twice daily; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIASTAT and STELAZINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIASTAT is classified as Category C. DIASTAT (diazepam) is classified as Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip and palate, when used during the first. STELAZINE is classified as Category C. First trimester: Limited data; possible increased risk of congenital malformations (neural tube defects, cardiovascular) based on some retrospective studies. Second/third trimester. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.